Alogabat
Alogabat is an α5 subunit-containing GABAA receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders and Angelman syndrome. It is taken by mouth.
As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome. It is under development by Roche.